Clinical trials: Acute Myeloid Leukemia (AML) With
Acute Myeloid Leukemia (AML)
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML
The purpose of this prospective phase III, open-label, randomized multicenter study is to evaluate whether Acute Myeloid Leukemia (AML) elderly patients in Complete Remission (CR) undergoing allogeneic hematopoietic stem cell…
- Trial name
- GITMO-AMLR2 (NCT01191957)
- Testing
- Busulphan plus Cyclophosphamide, Busulphan plus Fludarabine
- Where
- 26 sites in Israel, Italy
- Volunteers
- 252 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers
This trial investigates stem cell transplants from partially mismatched donors in patients with blood and bone marrow cancers. The trial will test two kinds of transplants - a full intensity transplant using a high dose of…
- Conditions
- Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Myeloid Leukaemia, Acute Lymphoblastic Leukaemia
- Trial name
- UK-Haplo (NCT01597219)
- Testing
- Reduced intensity haplodentical stem cell transplant, Myeloablative haploidentical stem cell transplant
- Where
- 12 sites in United Kingdom
- Volunteers
- 77 people
- Sponsor
- University College, London
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
To evaluate the safety and effectiveness of Sodium Stibogluconate in the treatment of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) with p53 mutation from a defined list.
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy, Temperature-Sensitive p53 Mutation
- Trial name
- NCT04906031
- Testing
- Sodium stibogluconate
- Where
- China
- Volunteers
- 5 people
- Sponsor
- First Affiliated Hospital of Jinan University
Acute Myeloid Leukemia, Exercise
A Study of a Home-based Exercise Intervention for Patients With Acute Myeloid Leukaemia (AML)
Fatigue is the most common and disabling symptom in acute myeloid leukaemia (AML). Studies in other cancer patients with fatigue have shown that exercise improves both fatigue and quality of life (QOL), but there are no such…
- Conditions
- Acute Myeloid Leukemia, Exercise, Fatigue, Quality of Life
- Trial name
- NCT00764231
- Testing
- Home-based exercise program, Wait list
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Toronto Rehabilitation Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
RATIONALE: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT01177371
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Case Comprehensive Cancer Center
AML (Acute Myeloid Leukemia)
VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial
This is a multicenter, prospective, single-arm clinical study designed to evaluate the efficacy and safety of the VA-CIG regimen (venetoclax combined with azacitidine, idarubicin, low-dose cytarabine and granulocyte…
- Trial name
- NCT07514832
- Testing
- Venetoclax, Azacitidine, Cytarabine, Idarubicin, G-CSF
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing 302 Hospital
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute…
- Trial name
- NCT04620681
- Testing
- CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes, Standard of Care Chemotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
This phase II trial investigates how well CPX-351 and ivosidenib work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has IDH1 mutation.
- Conditions
- Acute Myeloid Leukemia With Gene Mutations, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT04493164
- Testing
- Ivosidenib, Liposome-encapsulated Daunorubicin-Cytarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD…
- Conditions
- Acute Myelogenous Leukemia, B-cell Acute Lymphoblastic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myeloid Leukemia, Blast Crisis
- Trial name
- NCT02730312
- Testing
- XmAb14045
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Xencor, Inc.
Acute Myeloid Leukemia (AML)
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with…
- Trial name
- NCT03441555
- Testing
- Venetoclax, Alvocidib
- Where
- 14 sites in United States, Germany and 1 more
- Volunteers
- 36 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia, Myelodysplastic Syndrome
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase I trial studies the side effects and best dose of PLX51107 and how well it works with azacitidine in treating patients with acute myeloid leukemia or myelodysplastic syndrome.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
- Trial name
- NCT04022785
- Testing
- Azacitidine, BRD4 Inhibitor PLX51107
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes, Acute Myeloid Leukemia
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
In this trial the investigators aim to evaluate safety and efficacy of combination Ivosidenib (AG-120) and nivolumab in the context of adult patients with Isocitrate dehydrogenase-1 (IDH1) mutated acute myeloid leukemias (AML) or…
- Trial name
- NCT04044209
- Testing
- AG-120, Nivolumab
- Where
- United States
- Sponsor
- Yale University
AML
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission
Depending on the variant of the disease, patients are divided into 3 groups: A, B and C. Group A include patients with acute myeloid leukemia (AML) inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, group B - AML with…
- Trial name
- NCT05339204
- Testing
- allo-HSCT
- Where
- Russia
- Volunteers
- 75 people
- Sponsor
- National Research Center for Hematology, Russia
Relapsed or Refractory Acute Myeloid Leukemia
A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
Acute myeloid leukemia (AML) is one of the hematologic malignancies, for which patients typically undergo chemotherapy to achieve complete remission.
- Trial name
- NCT06879847
- Testing
- Salvage Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
RATIONALE: Keratinocyte growth factor may prevent symptoms of mucositis in patients receiving radiation therapy and chemotherapy.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00004132
- Testing
- filgrastim, palifermin, cyclophosphamide
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia, Myelocytic, Acute Myelodysplastic Syndromes, Myelodysplastic Syndromes
Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)
This study is to evaluate the safety and tolerability of vorinostat in combination with decitabine as well as the in vivo molecular and biological effects of vorinostat in patients with refractory or relapsed Acute Myelogenous…
- Trial name
- NCT00479232
- Testing
- vorinostat, decitabine
- Volunteers
- 71 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Myelogenous Leukemia
Epigenetic Reprogramming in Relapse/Refractory AML
This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
- Trial name
- NCT03263936
- Testing
- Decitabine, Vorinostat, Filgrastim (G-CSF)
- Where
- 33 sites in United States, Australia and 1 more
- Volunteers
- 37 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
AML/MDS, CMML
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-108 as Monotherapy and in Combination with Azacitidine in Subjects with…
- Conditions
- AML/MDS, CMML, Relapse, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04139434
- Testing
- LP-108, LP-108 and azacitidine
- Where
- 7 sites in United States, Spain
- Volunteers
- 32 people
- Sponsor
- Newave Pharmaceutical Inc
Acute Myeloid Leukemia
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
The goal of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of RVU120 when administered in combination with venetoclax to adult patients with acute myeloid leukemia…
- Trial name
- RIVER-81 (NCT06191263)
- Testing
- RVU120, Venetoclax
- Where
- 37 sites in France, Italy and 2 more
- Volunteers
- 98 people
- Sponsor
- Ryvu Therapeutics SA
Acute Myeloid Leukemia
Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy
This single-arm interventional study evaluated the short-term outcome of one 28-day cycle of venetoclax combined with a hypomethylating agent (azacitidine or decitabine) in adults with newly diagnosed acute myeloid leukemia who…
- Trial name
- NCT07773909
- Testing
- Venetoclax, Azacitidine, Decitabine
- Where
- Bangladesh
- Volunteers
- 24 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.